A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma - BeiGene Australia

Australia
- Australia
- Canada EN|FR
- China
- Germany
- Global
- Spain
- US

⟵ Back to Search Results

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Beigene Study ID

BGB-A317-302

ClinicalTrials.gov ID

NCT03430843

EudraCT Number

2017-003699-30

Clinical Drug Trials ID

CTR20171026

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

Study Overview

Sex: All

Age: 18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers? yes

No Study Documents

You will be redirected to

Click the link above to continue or CANCEL